Nasdaq · Healthcare
Natera, Inc. (NTRA)
As-reported financials and recent SEC filings for Natera, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$2.31B
Net income
$-208.2M
Net margin
-9.0%
Diluted EPS
$-1.52
ROE
-12.2%
P/E (TTM)
—
Market cap
$37.51B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $2.31B | $1.70B | $1.08B | $820.2M | $625.5M |
| Gross profit | — | — | — | — | — |
| Operating income | $-309.9M | $-222.3M | $-446.2M | $-541.0M | $-468.2M |
| Net income | $-208.2M | $-190.4M | $-434.8M | $-547.8M | $-471.7M |
| Diluted EPS | $-1.52 | $-1.53 | $-3.78 | $-5.57 | $-5.21 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-26
View on EDGAR →42026-06-26
View on EDGAR →1442026-06-24
View on EDGAR →1442026-06-24
View on EDGAR →42026-06-22
View on EDGAR →42026-06-17
View on EDGAR →42026-06-17
View on EDGAR →1442026-06-16
View on EDGAR →Go deeper on NTRA
Search Natera, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.